Skip to main content
SpringerLink
Log in

Drugs Hazardous to Healthcare Workers

Evaluation of Methods for Monitoring Occupational Exposure to Cytostatic Drugs

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

We review the literature concerning possible health risks for individuals (e.g. healthcare workers and pharmaceutical plant employees) occupationally exposed to cytostatic drugs. Cytostatic drugs possess toxic properties and may therefore cause mutagenic, carcinogenic and teratogenic effects. Hence, individuals handling these drugs in the course of their employment may face health risks. For this reason, it is important to monitor occupational exposure to these drugs.

An overview of exposure monitoring methods is presented and their value is discussed. Most studies involve nonselective methods for biological monitoring and biological effect monitoring, such as the urinary mutagenicity assay and analysis of chromosomal aberrations and sister-chromatid exchanges in peripheral blood lymphocytes. The disadvantages of these biological methods are that their sensitivity is low and it cannot be proved beyond any doubt that the results found were caused by occupational exposure to cytostatic drugs. For occupational health services it is important to have sensitive and specific methods for monitoring exposure to cytostatic drugs. One of the most promising methods seems to be the determination of cyclophosphamide in urine using gas chromatographytandem mass spectrometry.

Several studies have demonstrated exposure to cyclophosphamide and other cytostatic drugs, even when protective measures were taken and safety guidelines were followed. To estimate the magnitude of any health effects arising from this exposure, we calculated the risk of cancer due to occupational exposure to cyclophosphamide on the basis of available human and animal dose-response data and the amounts of cyclophosphamide found in urine. The initial results show an extra cancer risk for pharmacy technicians and nurses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Black DJ, Livingston RB. Antineoplastic drags in 1990: a review (part I). Drugs 1990; 39: 489–501

    Article  PubMed  CAS  Google Scholar 

  2. Black DJ, Livingston RB. Antineoplastic drags in 1990: a review (part II). Drags 1990; 39: 652–73

    Article  CAS  Google Scholar 

  3. Sorsa M, Hemminki K, Vainio H. Occupational exposure to anticancer drugs — potential and real hazards. Mutat Res 1985; 154: 135–49

    Article  PubMed  CAS  Google Scholar 

  4. Ladik CF, Stoehr GP, Maurer MA. Precautionary measures in the preparation of antineoplastics. Am J Hosp Pharm 1980; 37: 1185–6

    Google Scholar 

  5. McDiarmid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med 1988; 30: 984–7

    Article  PubMed  CAS  Google Scholar 

  6. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Vol. 26: some antineoplastic and immunosuppressive agents. Lyon, France: IARC, 1981

    Google Scholar 

  7. International Agency for Research on Cancer. IARC scientific publications. Nr. 78. Carcinogenicity of alkylating cytostatic drugs. Lyon, France: IARC, 1986

    Google Scholar 

  8. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Suppl. 7. Lyon, France: IARC, 1987

    Google Scholar 

  9. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Vol. 50: pharmaceutical drugs. Lyon, France: IARC, 1990

    Google Scholar 

  10. Ferguson LR. Mutagenicity of anticancer drags. Mutat Res 1996; 355: 1–261

    Article  PubMed  Google Scholar 

  11. Hemminki K, Kyyrönen P, Lindbohm M-L. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drags, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health 1985; 39: 141–7

    Article  PubMed  CAS  Google Scholar 

  12. Selevan SG, Lindbohm M-L, Homung RW, et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985; 313: 1173–8

    Article  PubMed  CAS  Google Scholar 

  13. Shortridge LA, Lemasters GK, Valanis B, et al. Menstrual cycles in nurses handling antineoplastic drags. Cancer Nurs 1995; 18: 439–44

    Article  PubMed  CAS  Google Scholar 

  14. Skov T, Maarup B, Olsen J, et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drags. Br J Ind Med 1992; 49: 855–61

    PubMed  CAS  Google Scholar 

  15. Taskinen H, Lindbohm M-L, Hemminki K. Spontaneous abortions among women working in the pharmaceutical industry. Br J Ind Med 1986; 43: 199–205

    PubMed  CAS  Google Scholar 

  16. Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Longterm case-control follow-up study. Am J Med 1987; 83: 1–9

    Article  PubMed  CAS  Google Scholar 

  17. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukomogen than cyclophosphamide. Ann Intern Med 1986; 105: 360–7

    PubMed  CAS  Google Scholar 

  18. Sessink PJM, van de Kerkhof MCA, Anzion RBM, et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health 1994; 49: 165–9

    Article  PubMed  CAS  Google Scholar 

  19. Sessink PJM, Wittenhorst BCJ, Anzion RBM, et al. Exposure of pharmacy technicians to antineoplastic agents; reevaluation after additional protective measures. Arch Environ Health 1997; 52: 240–4

    Article  PubMed  CAS  Google Scholar 

  20. Slevin ML, Ang LM, Johnston A, et al. The efficiency of protective gloves used in the handling of cytotoxic drags. Cancer Chemother Pharmacol 1984; 12: 151–3

    Article  PubMed  CAS  Google Scholar 

  21. Laidlaw JL, Connor TH, Theiss JC, et al. Permeability of latex and polyvinyl chloride gloves to 20 antineoplastic drags. Am J Hosp Pharm 1984; 41: 2618–23

    PubMed  CAS  Google Scholar 

  22. Stoikes ME, Carlson JD, Farris FF, et al. Permeability of latex and polyvinyl chloride gloves to fluorouracil and methotrexate. Am J Hosp Pharm 1987; 44: 1341–6

    PubMed  CAS  Google Scholar 

  23. Colligan SA, Horstman SW. Permeation of cancer chemotherapeutic drugs through glove materials under static and flexed conditions. Appl Occup Environ Hyg 1990; 5: 848–52

    Article  CAS  Google Scholar 

  24. Anderson RW, Puckett WH Jr, Dana WJ, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39: 1881–7

    PubMed  CAS  Google Scholar 

  25. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990; 47: 1033–49

    Google Scholar 

  26. Vereniging van Integrale Kankercentra. Workbook for cytostatic drags [in Dutch]. Utrecht, The Netherlands: VIK, 1997

    Google Scholar 

  27. Skov T. Handling antineoplastic drags in the European Community countries. Eur J Cancer Prev 1993; 2: 43–6

    Article  PubMed  CAS  Google Scholar 

  28. Opiolka S, Mölter W, Goldschmidt R, et al. Umgang mit Zytostatika. März: Krankenhaus Technik, 1998: 56-8

  29. Offical Journal of the European Communities. Council directive of 12 June 1989 on the introduction of measures to encourage improvements in the safety and health of workers at work (89/391/EEC). No. L 183 1–8, 1989 Jun 29

  30. Offical Journal of the European Communities. Council directive of 28 June 1990 on the protection of workers from the risks related to exposure to carcinogens at work (90/394/EEC). No. L 196 1-7. 1990 Jul 26

  31. Friberg A. Protector-projektet vid Östra sjukhuset i Göteborg: kontaminations-och säkerhetsaspekter vid hantering av cytostatika [in Swedish]. Sjukhusfarmaci 1996; 2: 35–45

    Google Scholar 

  32. Gustavsson B. Evaluation of a technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Practice 1997; 3: 16

    Google Scholar 

  33. DeWerk Neal A, Wadden RA, Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 1983; 40: 597–601

    PubMed  CAS  Google Scholar 

  34. Kleinberg ML, Quinn MJ. Airborne drag levels in a laminarflow hood. Am J Hosp Pharm 1981; 38: 1301–3

    PubMed  CAS  Google Scholar 

  35. Pyy L, Sorsa M, Hakala E. Ambient monitoring of cyclophosphamide in manufacture and hospitals. Am Ind Hyg Assoc J 1988; 49: 314–7

    Article  PubMed  CAS  Google Scholar 

  36. Sorsa M, Pyy L, Salomaa S, et al. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 1988; 204: 465–79

    Article  PubMed  CAS  Google Scholar 

  37. Sorsa M, Pyy L. Exposure assessment of workers in the production of cyclophosphamide. Pol J Occup Med 1990; 3: 185–9

    PubMed  CAS  Google Scholar 

  38. Friederich U, Molko F, Hofmann V, et al. Limitations of the Salmonella/mammalian microsome assay (Ames test) to determine occupational exposure to cytostatic drags. Eur J Cancer Clin Oncol 1986; 22: 567–75

    Article  PubMed  CAS  Google Scholar 

  39. Sessink PJM, Anzion RBM, van den Broek PHH, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 1992; 14: 16–22

    Article  PubMed  CAS  Google Scholar 

  40. Sessink PJM, Boer KA, Scheefhals APH, et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992; 64: 105–12

    Article  PubMed  CAS  Google Scholar 

  41. Sessink PJM, de Roos JHC, Pierik FH, et al. Occupational exposure of animal caretakers to cyclophosphamide. J Occup Med 1993; 35: 47–52

    PubMed  CAS  Google Scholar 

  42. Sessink PJM, Friemèl NSS, Anzion RBM, et al. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health 1994; 65: 401–3

    Article  PubMed  CAS  Google Scholar 

  43. Sessink PJM, Timmermans JL, Anzion RBM, et al. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil: determination of α-fluoro-β-alanine in urine. J Occup Med 1994; 36: 79–83

    PubMed  CAS  Google Scholar 

  44. Bos RP, Weissenberger BFJ, Anzion RBM. α-Fluoro-β-alanine in urine of workers occupationally exposed to 5-fluorouracil in a 5-fluorouracil-producing factory. Biomarkers 1998; 3: 81–7

    Article  CAS  Google Scholar 

  45. McDiarmid MA, Egan T, Furio M, et al. Sampling for airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm 1986; 43: 1942–5

    PubMed  CAS  Google Scholar 

  46. Nygren O, Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health 1997; 70: 209–14

    Article  PubMed  CAS  Google Scholar 

  47. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm 1996; 53: 2713–23

    PubMed  CAS  Google Scholar 

  48. Bos RP, Sessink PJM. Biomonitoring of occupational exposure to cytostatic anticancer drugs. Rev Environ Health 1997; 12: 43–58

    Article  PubMed  CAS  Google Scholar 

  49. Tuffnell PG, Gannon MT, Dong A, et al. Limitation of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs. Am J Hosp Pharm 1986; 43: 344–8

    PubMed  CAS  Google Scholar 

  50. Bos RP, Jongeneelen FJ. Nonselective and selective methods for biological monitoring of exposure to coal-tar products. IARC scientific publications 89; 389–95. Lyon, France: IARC, 1988

    Google Scholar 

  51. Falck K, Gröhn P, Sorsa M, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; I: 1250–1

    Article  Google Scholar 

  52. Staiano N, Gallelli JF, Adamson RH, et al. Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet 1981; 615-6

  53. Wilson JP, Solimando DA. Antineoplastics: a safety hazard? Am J Hosp Pharm 1981; 38: 624

    PubMed  CAS  Google Scholar 

  54. Bos RP, Leenaars AO, Theuws JLG, et al. Mutagenicity of urine from nurses handling cytostatic drugs: influence of smoking. Int Arch Occup Environ Health 1982; 50: 359–69

    Article  PubMed  CAS  Google Scholar 

  55. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 1982; 42: 4792–6

    PubMed  CAS  Google Scholar 

  56. Theiss JC. Hospital personnel who handle anticancer drugs may face risks. JAMA 1982; 247: 11–2

    Article  Google Scholar 

  57. Hoffman DM. Lack of urine mutagenicity of nurses administering pharmacy prepared doses of antineoplastic agents. Am J IV Ther Clin Nutr 1983; 10: 28–31

    Google Scholar 

  58. Kolmodin-Hedman B, Hartvig P, Sorsa M, et al. Occupational handling of cytostatic drugs. Arch Toxicol 1983; 54: 25–33

    Article  PubMed  CAS  Google Scholar 

  59. Gibson JF, Gompertz D, Hedworth-Whitty RB. Mutagenicity of urine from nurses handling cytotoxic drugs. Lancet 1984; 1: 100–1

    Article  PubMed  CAS  Google Scholar 

  60. Venitt S, Crofton-Sleigh C, Hunt J, et al. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption. Lancet 1984; I: 74–7

    Article  Google Scholar 

  61. Barale R, Sozzi G, Toniolo P, et al. Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat Res 1985; 157: 235–40

    Article  PubMed  CAS  Google Scholar 

  62. Cloak MM, Connor ThH, Stevens KR, et al. Occupational exposure of nursing personnel to antineoplastic agents. Oncol Nurs Forum 1985; 12: 33–9

    PubMed  CAS  Google Scholar 

  63. Everson RB, Ratcliffe JM, Flack PM, et al. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures. Cancer Res 1985; 45: 6487–97

    PubMed  CAS  Google Scholar 

  64. Benhamou S, Callais F, Sancho-Garnier H, et al. Mutagenicity in urine from nurses handling cytostatic agents. Eur J Cancer Clin Oncol 1986; 22: 1489–93

    Article  PubMed  CAS  Google Scholar 

  65. Breed ASPM, ten Hoopen AJ, Theuws JLG, et al. Cytostaticabereiding en toediening, een gezondheidsrisico voor verpleegkundigen? [in Dutch] Tijdschr Sociale Gezondheit 1986; 64: 361–5

    Google Scholar 

  66. Connor TH, Theiss JC, Anderson RW, et al. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Am J Hosp Pharm 1986; 43: 1236–9

    PubMed  CAS  Google Scholar 

  67. Fransman LG, van der Put MTh, van Rijckevorsel JLA, et al. Verslag van het onderzoek naar de blootstelling aan parenterale (genotoxische) cytostatica bij werknemers in de gezondheidszorg [in Dutch]. The Hague: Rijks Bedrijfsgezondheids- en Bedrijfsveiligheidsdienst, 1986

    Google Scholar 

  68. Pohlová H, Cerná M, Rössner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res 1986; 174: 213–7

    Article  PubMed  Google Scholar 

  69. Stacker I, Hirsch A, Doloy T, et al. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986; 57: 195–205

    Article  Google Scholar 

  70. Courtois YA, Beaubestre C, Benhamou S, et al. Détermination de la génotoxicité urinaire: application au dépistage de l’exposition tabagique et/ou professionelle [in French]. Ann Pharm Fr 1987; 45: 289–300

    PubMed  CAS  Google Scholar 

  71. Caudell KA, Vredevoe DL, Dietrich MF, et al. Quantification of urinary mutagens in nurses during potential antineoplastic agent exposure: a pilot study with concurrent environmental and dietary control. Cancer Nurs 1988; 11: 41–50

    Article  PubMed  CAS  Google Scholar 

  72. Poyen D, Botta A, de Meo M, et al. Etude de la mutagénicité urinaire d’agents hospitaliers féminins: influence primordiale du tabagisme [in French]. Arch Mal Prof 1988; 49: 11–6

    Google Scholar 

  73. Poyen D, DeMéo MP, Botta A, et al. Handling of cytostatic drugs and urine mutagenesis. Int Arch Occup Environ Health 1988; 61: 183–8

    Article  PubMed  CAS  Google Scholar 

  74. Krepinsky A, Bryant DW, Davison L, et al. Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ Mol Mutagen 1990; 15: 83–92

    Article  PubMed  CAS  Google Scholar 

  75. Thiringer G, Granung G, Holmén A, et al. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health 1991; 17: 133–8

    Article  PubMed  CAS  Google Scholar 

  76. DeMéo MP, Mérono S, DeBaille AD, et al. Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials. Int Arch Occup Environ Health 1995; 66: 363–8

    Article  PubMed  Google Scholar 

  77. Ames BN. Dietary carcinogens and anticarcinogens. Science 1983; 221: 1256–65

    Article  PubMed  CAS  Google Scholar 

  78. Baker R, Arlauskas A, Bonin A, et al. Detection of mutagenic activity in human urine following fried pork or bacon meals. Cancer Lett 1982; 16: 81–9

    Article  PubMed  CAS  Google Scholar 

  79. Sasson IM, Coleman DT, La Voie EJ, et al. Mutagens in human urine: effect of cigarette smoking and diet. Mutat Res 1983; 158: 149–57

    Google Scholar 

  80. Evelo CTA, Bos RP, Peters JGP, et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 1986; 58: 151–5

    Article  PubMed  CAS  Google Scholar 

  81. Jagun O, Ryan M, Waldron HA. Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet 1982; II: 443–4

    Article  Google Scholar 

  82. Sarto F, Trevisan A, Tomanin R, et al. Chromosomal aberrations, sister chromatid exchanges, and urinary thioethers in nurses handling antineoplastic drugs. Am J Ind Med 1990; 18: 689–95

    Article  PubMed  CAS  Google Scholar 

  83. Bahyan S, Burgaz S, Karakaya AE. Urinary thioether excretion in nurses at an oncology department. J Clin Pharm Ther 1987; 12: 303–6

    Article  Google Scholar 

  84. Burgaz S, Özdamar YN, Karakaya AE. A signal assay for the detection of genotoxic compounds: application on the urines of cancer patients on chemotherapy and of nurses handling cytotoxic drugs. Human Toxicol 1988; 7: 557–60

    Article  CAS  Google Scholar 

  85. Hirst M, Tse S, Mills DG, et al. Occupational exposure to cyclophosphamide. Lancet 1984; I: 186–8

    Article  Google Scholar 

  86. Ensslin AS, Stoll Y, Pethran A, et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994; 51: 229–33

    Article  PubMed  CAS  Google Scholar 

  87. Sessink PJM, Cerná M, Rössner P, et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994; 309: 193–9

    Article  PubMed  CAS  Google Scholar 

  88. Sessink PJM, Kroese ED, van Kranen HJ, et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 1995; 67: 317–23

    Article  PubMed  CAS  Google Scholar 

  89. Sessink PJM. Monitoring of occupational exposure to antineoplastic agents [dissertation]. Nijmegen: University of Nijmegen, 1996. ISBN 90-803205-1

  90. Ensslin AS, Huber R, Pethran A, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetic studies. Int Arch Occup Environ Health 1997; 70: 205–8

    Article  PubMed  CAS  Google Scholar 

  91. Sessink PJM, Scholtes MM, Anzion RBM, et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr 1993; 616: 333–7

    Article  PubMed  CAS  Google Scholar 

  92. Ensslin AS, Pethran A, Schierl R, et al. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health 1994; 65: 339–42

    Article  PubMed  CAS  Google Scholar 

  93. Mader RM, Rizovski B, Steger GG, et al. Determination of methotrexate in human urine at nanomolar levels by high-performance liquid chromatography with column switching. J Chromatogr 1993; 613: 311–6

    Article  PubMed  CAS  Google Scholar 

  94. Norppa H, Sorsa M, Vainio H, et al. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980; 6: 299–301

    Article  PubMed  CAS  Google Scholar 

  95. Waksvik H, Klepp O, Brøgger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981; 65: 607–10

    PubMed  CAS  Google Scholar 

  96. Szigeti M, Fekete G, Szollár J. The effect of regular cytostatic handling on the sister-chromatid exchanges in hospital nurses. Mutat Res 1982; 97: 227

    Google Scholar 

  97. Stiller A, Obe G, Boll I, et al. No elevation of the frequencies of chromosomal alterations as a consequence of handling cytostatic drugs: analyses with peripheral blood and urine of hospital personnel. Mutat Res 1983; 121: 253–9

    Article  PubMed  CAS  Google Scholar 

  98. Nikula E, Kiviniitty K, Leisti J, et al. Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand J Work Environ Health 1984; 10: 71–4

    Article  PubMed  CAS  Google Scholar 

  99. Jordan DK, Patil SR, Jochimsen PR, et al. Sister chromatid exchange analysis in nurses handling antineoplastic drugs. Cancer Invest 1986; 4: 101–7

    Article  PubMed  CAS  Google Scholar 

  100. Benhamou S, Pot-Deprun J, Sancho-Garnier H, et al. Sister chromatid exchanges and chromosomal aberrations in lymphocytes of nurses handling cytostatic agents. Int J Cancer 1988; 41: 350–3

    Article  PubMed  CAS  Google Scholar 

  101. Oestreicher U, Stephan G, Glatzel M. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat Res 1990; 242: 271–7

    Article  PubMed  CAS  Google Scholar 

  102. Milkovic-Kraus S, Horvat D. Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs. Am J Ind Med 1991; 19: 771–4

    Article  PubMed  CAS  Google Scholar 

  103. Cooke J, Williams J, Morgan RJ, et al. Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 1991; 48: 1199–205

    PubMed  CAS  Google Scholar 

  104. Sardas S, Gök S, Karakaya A. Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs. Toxicol Lett 1991; 55: 311–5

    Article  PubMed  CAS  Google Scholar 

  105. Grummt T, Grummt H-J, Schott G. Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res 1993; 302: 19–24

    Article  PubMed  CAS  Google Scholar 

  106. Fuchs J, Hengstler JG, Jung D, et al. DNA damage in nurses handling antineoplastic agents. Mutat Res 1995; 342: 17–23

    Article  PubMed  CAS  Google Scholar 

  107. Oesch F, Hengstler JG, Arand M, et al. Detection of primary DNA damage: applicability to biomonitoring of genotoxic occupational exposure and in clinical therapy. Pharmacogenetics 1995; 5 Spec. No.: S118–22

    Article  PubMed  CAS  Google Scholar 

  108. Brumen V, Horvat D. Work environment influence on cytostatics-induced genotoxicity in oncologic nurses. Am J Ind Med 1996; 30: 67–71

    Article  PubMed  CAS  Google Scholar 

  109. Chrysostomou A, Seshadri R, Morley AA. Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust NZJ Med 1984; 14: 831–4

    Article  CAS  Google Scholar 

  110. Hüttner E, Mergner U, Braun R, et al. Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production. Mutat Res 1990; 243: 101–7

    Article  PubMed  Google Scholar 

  111. Sessink PJM, Verplanke AJW, Herber RFM, et al. Occupational exposure to antineoplastic agents and parameters for renal dysfunction. Int Arch Occup Environ Health 1997; 69: 215–8

    Article  PubMed  CAS  Google Scholar 

  112. Lassila O, Toivanen A, Nordman E. Immune function in nurses handling cytostatic drugs. Lancet 1980; 482

    Google Scholar 

  113. Advies inzake grenswaarden voor genotoxisch carcinogene Stoffen [in Dutch]. Zoetermeer, The Netherlands: Arboraad, 1992

Download references

Author information

Authors and Affiliations

  1. Exposure Control, P.O. Box 467, 6600, AL Wijchen, The Netherlands

    Paul J. M. Sessink

  2. Department of Toxicology, Faculty of Medical Sciences, University of Nijmegen, Nijmegen, The Netherlands

    Rob P. Bos

Authors
  1. Paul J. M. Sessink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rob P. Bos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sessink, P.J.M., Bos, R.P. Drugs Hazardous to Healthcare Workers. Drug-Safety 20, 347–359 (1999). https://doi.org/10.2165/00002018-199920040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920040-00004

Keywords

Search

Navigation